Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 22

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes

Lombardi, Angela, Concepcion, Erlinda, Hou, Hanxi, Arib, Hanane, Mezei, Mihaly, Osman, Roman, Tomer, Yaron · 2020 · Journal of Autoimmunity

Abstract

Over the past four decades, the number of people with Type 1 Diabetes (T1D) has increased by 4% per year, making it an important public health challenge. Currently, no curative therapy exists for T1D and the only available treatment is insulin replacement. HLA-DQ8 has been shown to present antigenic islet peptides driving the activation of CD4+ T-cells in T1D patients. Specifically, the insulin peptide InsB:9-23 activates self-reactive CD4+ T-cells, causing pancreatic beta cell destruction. The aim of the current study was to identify retro-inverso-D-amino acid based peptides (RI-D-peptides) that can suppress T-cell activation by blocking the presentation of InsB:9-23 peptide within HLA-DQ8 pocket. We identified a RI-D-peptide (RI-EXT) that inhibited InsB:9-23 binding to recombinant HLA-DQ8 molecule, as well as its binding to DQ8 expressed on human B-cells. RI-EXT prevented T-cell activation in a cellular antigen presentation assay containing human DQ8 cells loaded with InsB:9-23 peptide and murine T-cells expressing a human T-cell receptor specific for the InsB:9-23–DQ8 complex. Moreover, RI-EXT blocked T-cell activation by InsB:9-23 in a humanized DQ8 mice both ex vivo and in vivo, as shown by decreased production of IL-2 and IFN-γ and reduced lymphocyte proliferation. Interestingly, RI-EXT also blocked lymphocyte activation and proliferation by InsB:9-23 in PBMCs isolated from recent onset DQ8-T1D patients. In summary, we discovered a RI-D-peptide that blocks InsB:9-23 binding to HLA-DQ8 and its presentation to T-cells in T1D. These findings set the stage for using our approach as a novel therapy for patients with T1D and potentially other autoimmune diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaut.2020.102543

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 58

  1. Norris, 2020, Type 1 diabetes-early life origins and changing epidemiology, Lancet Diabetes Endocrinol, 8, 226, 10.1016/S2213-8587(19)30412-7 · DOI · Paper page
  2. Maahs, 2010, Epidemiology of type 1 diabetes, Endocrinol Metab. Clin. N. Am., 39, 481, 10.1016/j.ecl.2010.05.011 · DOI · Paper page
  3. Dabelea, 2014, Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009, Jama, 311, 1778, 10.1001/jama.2014.3201 · DOI · Paper page
  4. Barnett, 2018, Type 1 diabetes, Lancet, 391, 195, 10.1016/S0140-6736(18)30024-2 · DOI · Paper page
  5. Lombardi, 2018, Interferon alpha: the key trigger of type 1 diabetes, J. Autoimmun., 94, 7, 10.1016/j.jaut.2018.08.003 · DOI
  6. Ahmed, 2019, A public BCR present in a unique dual-receptor-expressing lymphocyte from type 1 diabetes patients encodes a potent T cell autoantigen, Cell, 177, 1583, 10.1016/j.cell.2019.05.007 · DOI
  7. Wong, 2016, Diabetic retinopathy, Nat. Rev. Di. Prim., 2, 16012, 10.1038/nrdp.2016.12 · DOI · Paper page
  8. Barbetti, 2019, Insulin: still a miracle after all these years, J. Clin. Invest., 130, 3045, 10.1172/JCI130310 · DOI
  9. Cryer, 2008, The barrier of hypoglycemia in diabetes, Diabetes, 57, 3169, 10.2337/db08-1084 · DOI · Paper page
  10. Borus, 2010, Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention, Curr. Opin. Pediatr., 22, 405, 10.1097/MOP.0b013e32833a46a7 · DOI · Paper page
  11. Lee, 2001, Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes, Nat. Immunol., 2, 501, 10.1038/88694 · DOI · Paper page
  12. Nakayama, 2005, Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice, Nature, 435, 220, 10.1038/nature03523 · DOI · Paper page
  13. Alleva, 2001, A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin, J. Clin. Invest., 107, 173, 10.1172/JCI8525 · DOI · Paper page
  14. Yoshida, 2010, The diabetogenic mouse MHC class II molecule I-Ag7 is endowed with a switch that modulates TCR affinity, J. Clin. Invest., 120, 1578, 10.1172/JCI41502 · DOI
  15. Michels, 2017, Islet-derived CD4 T cells targeting proinsulin in human autoimmune diabetes, Diabetes, 66, 722, 10.2337/db16-1025 · DOI · Paper page
  16. Tan, 2017, Type 1 diabetes induction in humanized mice, Proc. Natl. Acad. Sci. U.S.A., 114, 10954, 10.1073/pnas.1710415114 · DOI
  17. Zhang, 2014, Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes, Proc. Natl. Acad. Sci. U.S.A., 111, 2656, 10.1073/pnas.1323436111 · DOI
  18. Ostrov, 2018, Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes, J. Clin. Invest., 128, 1888, 10.1172/JCI97739 · DOI
  19. Fosgerau, 2015, Peptide therapeutics: current status and future directions, Drug Discov. Today, 20, 122, 10.1016/j.drudis.2014.10.003 · DOI · Paper page
  20. Simulaid, 2010, A simulation facilitator and analysis program, J. Comput. Chem., 31, 2658, 10.1002/jcc.21551 · DOI
  21. Di Lorenzo, 2007, Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes, Clin. Exp. Immunol., 148, 1, 10.1111/j.1365-2249.2006.03244.x · DOI · Paper page
  22. Broughton, 2012, Biased T cell receptor usage directed against human leukocyte antigen DQ8-restricted gliadin peptides is associated with celiac disease, Immunity, 37, 611, 10.1016/j.immuni.2012.07.013 · DOI
  23. White, 1993, Antigen recognition properties of mutant V beta 3+ T cell receptors are consistent with an immunoglobulin-like structure for the receptor, J. Exp. Med., 177, 119, 10.1084/jem.177.1.119 · DOI
  24. De Vitis, 2011, Tyr phosphatase-mediated P-ERK inhibition suppresses senescence in EIA + v-raf transformed cells, which, paradoxically, are apoptosis-protected in a MEK-dependent manner, Neoplasia, 13, 120, 10.1593/neo.101152 · DOI
  25. Lombardi, 2017, Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells, Sci. Rep., 7, 15823, 10.1038/s41598-017-15283-y · DOI
  26. Lee, 2017, CD40 signaling in graves disease is mediated through canonical and noncanonical thyroidal nuclear factor kappaB activation, Endocrinology, 158, 410, 10.1210/en.2016-1609 · DOI
  27. Blackard, 2017, A preliminary analysis of hepatitis C virus in pancreatic islet cells, Virol. J., 14, 237, 10.1186/s12985-017-0905-3 · DOI
  28. Kudva, 2002, Modulation of insulitis and type 1 diabetes by transgenic HLA-DR3 and DQ8 in NOD mice lacking endogenous MHC class II, Hum. Immunol., 63, 987, 10.1016/S0198-8859(02)00435-4 · DOI
  29. Tzou, 2008, Autoimmune hypophysitis of SJL mice: clinical insights from a new animal model, Endocrinology, 149, 3461, 10.1210/en.2007-1692 · DOI
  30. Johnson, 2018, Identification of novel mycobacterial targets for murine CD4(+) T-cells by IFNgamma ELISPOT, Methods Mol. Biol., 1808, 143, 10.1007/978-1-4939-8567-8_12 · doi:10.1007/978-1-4939-8567-8_12
  31. Sengar, 1994, Comprehensive typing of DQB1 alleles by PCR-RFLP, Tissue Antigens, 43, 242, 10.1111/j.1399-0039.1994.tb02332.x · doi:10.1111/j.1399-0039.1994.tb02332.x
  32. Turner, 2018, Single molecule real-time DNA sequencing of HLA genes at ultra-high resolution from 126 International HLA and Immunogenetics Workshop cell lines, Hla, 91, 88, 10.1111/tan.13184 · DOI
  33. Coppieters, 2012, Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients, J. Exp. Med., 209, 51, 10.1084/jem.20111187 · DOI · Paper page
  34. Bloomgren, 2012, Risk of natalizumab-associated progressive multifocal leukoencephalopathy, N. Engl. J. Med., 366, 1870, 10.1056/NEJMoa1107829 · DOI · Paper page
  35. Liu, 2016, D-peptides as recognition molecules and therapeutic agents, Chem. Rec., 16, 1772, 10.1002/tcr.201600005 · DOI
  36. Teyton, 2007, The saga of MHC-bound peptides: a renaissance for antigen presentation?, J. Clin. Invest., 117, 3164, 10.1172/JCI33997 · doi:10.1172/jci33997
  37. Vlieghe, 2010, Synthetic therapeutic peptides: science and market, Drug Discov. Today, 15, 40, 10.1016/j.drudis.2009.10.009 · DOI · Paper page
  38. Craik, 2013, The future of peptide-based drugs, Chem. Biol. Drug Des., 81, 136, 10.1111/cbdd.12055 · DOI · Paper page
  39. Spear, 2018, Altered peptide ligands impact the diversity of polyfunctional phenotypes in T cell receptor gene-modified T cells, Mol. Ther., 26, 996, 10.1016/j.ymthe.2018.01.015 · DOI
  40. Onengut-Gumuscu, 2005, The genetics of type 1 diabetes: lessons learned and future challenges, J. Autoimmun., 25, 34, 10.1016/j.jaut.2005.09.007 · DOI
  41. Jahromi, 2006, Genetic determinants of type 1 diabetes across populations, Ann. N. Y. Acad. Sci., 1079, 289, 10.1196/annals.1375.044 · DOI
  42. Cucca, 2001, The HLA-DPB1--associated component of the IDDM1 and its relationship to the major loci HLA-DQB1, -DQA1, and -DRB1, Diabetes, 50, 1200, 10.2337/diabetes.50.5.1200 · DOI
  43. Nakayama, 2007, Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity, J. Clin. Invest., 117, 1835, 10.1172/JCI31368 · DOI
  44. Wucherpfennig, 2001, Insights into autoimmunity gained from structural analysis of MHC-peptide complexes, Curr. Opin. Immunol., 13, 650, 10.1016/S0952-7915(01)00274-6 · DOI
  45. Eisenbarth, 2002, Insulin autoimmunity: prediction/precipitation/prevention type 1A diabetes, Autoimmun. Rev., 1, 139, 10.1016/S1568-9972(02)00035-6 · DOI
  46. Achenbach, 2004, Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes, J. Clin. Invest., 114, 589, 10.1172/JCI200421307 · DOI · Paper page
  47. Yu, 2000, Binding of conserved islet peptides by human and murine MHC class II molecules associated with susceptibility to type I diabetes, Eur. J. Immunol., 30, 2497, 10.1002/1521-4141(200009)30:9<2497::AID-IMMU2497>3.0.CO;2-J · DOI
  48. Rosener, 2018, A d-enantiomeric peptide interferes with heteroassociation of amyloid-beta oligomers and prion protein, J. Biol. Chem., 293, 15748, 10.1074/jbc.RA118.003116 · DOI
  49. Liu, 2010, D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms, Proc. Natl. Acad. Sci. U.S.A., 107, 14321, 10.1073/pnas.1008930107 · DOI · Paper page
  50. Gregori, 2017, Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Abeta peptide, Nanomed. Nanotechnol. Biol. Med., 13, 723, 10.1016/j.nano.2016.10.006 · DOI
  51. Pescarolo, 2001, A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems, Faseb. J. : Off. Publ. Fed. Am. Soc. Exp. Biol., 15, 31, 10.1096/fj.00-0422fje · DOI
  52. Shaltiel-Karyo, 2010, Inhibiting alpha-synuclein oligomerization by stable cell-penetrating beta-synuclein fragments recovers phenotype of Parkinson's disease model flies, PloS One, 5, 10.1371/journal.pone.0013863 · DOI
  53. Srinivasan, 2001, A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro, J. Immunol., 167, 578, 10.4049/jimmunol.167.1.578 · DOI
  54. Sohnlein, 2000, Epitope spreading and a varying but not disease-specific GAD65 antibody response in Type I diabetes. The Childhood Diabetes in Finland Study Group, Diabetologia, 43, 210, 10.1007/s001250050031 · DOI
  55. Prasad, 2012, Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading, J. Autoimmun., 39, 347, 10.1016/j.jaut.2012.04.005 · DOI
  56. Green, 2007, Celiac disease, N. Engl. J. Med., 357, 1731, 10.1056/NEJMra071600 · DOI · Paper page
  57. Ji, 2013, Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis, J. Immunol., 191, 5074, 10.4049/jimmunol.1300407 · DOI
  58. Nakayama, 2019, Determining antigen specificity of human islet infiltrating T cells in type 1 diabetes, Front. Immunol., 10, 365, 10.3389/fimmu.2019.00365 · DOI

Cited by

See all 22

Metadata

Authors
Lombardi, A., Concepcion, E., Hou, H., Arib, H., Mezei, M., Osman, R., & Tomer, Y.
Venue
Journal of Autoimmunity
Publisher
Elsevier BV
Published
2020-12
Volume
115
Pages
102543
ISSN
0896-8411
Cited by
22
References
12
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health
  • Juvenile Diabetes Research Foundation United States of America

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.